BSE Live
Mar 20, 16:01Prev. Close
161.30
Open Price
161.70
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 20, 15:58Prev. Close
161.41
Open Price
162.33
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
170.05 (110)
| Balance Sheet of Marksans Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 40.93 | 40.93 | 40.93 | 40.93 | 40.93 | |
| Total Share Capital | 40.93 | 50.93 | 50.93 | 51.93 | 53.43 | |
| Reserves and Surplus | 464.69 | 429.64 | 388.04 | 377.95 | 369.27 | |
| Total Reserves and Surplus | 464.69 | 429.64 | 388.04 | 377.95 | 369.27 | |
| Total Shareholders Funds | 505.63 | 480.57 | 438.97 | 429.88 | 422.70 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax Liabilities [Net] | 10.79 | 7.03 | 6.01 | 5.34 | 0.31 | |
| Other Long Term Liabilities | 12.52 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 1.47 | 1.36 | 1.08 | 0.96 | 0.00 | |
| Total Non-Current Liabilities | 24.79 | 8.39 | 7.09 | 6.30 | 0.31 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 0.00 | 77.33 | 66.31 | 73.23 | 40.62 | |
| Trade Payables | 56.65 | 37.23 | 33.68 | 20.60 | 31.41 | |
| Other Current Liabilities | 12.16 | 7.91 | 10.84 | 3.82 | 0.68 | |
| Short Term Provisions | 0.55 | 0.56 | 0.40 | 11.93 | 38.49 | |
| Total Current Liabilities | 69.37 | 123.03 | 111.22 | 109.59 | 111.19 | |
| Total Capital And Liabilities | 599.78 | 611.99 | 557.29 | 545.77 | 534.20 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 110.35 | 97.19 | 87.88 | 91.90 | 90.32 | |
| Intangible Assets | 4.84 | 5.43 | 0.01 | 2.02 | 7.15 | |
| Capital Work-In-Progress | 0.00 | 0.00 | 0.00 | 0.36 | 0.00 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 115.18 | 102.61 | 87.89 | 94.28 | 97.47 | |
| Non-Current Investments | 236.07 | 236.07 | 236.07 | 234.29 | 231.44 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 1.25 | |
| Other Non-Current Assets | 4.47 | 1.29 | 0.82 | 0.59 | 0.00 | |
| Total Non-Current Assets | 355.73 | 339.98 | 324.78 | 329.16 | 330.16 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 74.60 | 70.36 | 42.29 | 29.24 | 43.74 | |
| Trade Receivables | 161.87 | 177.83 | 168.87 | 154.80 | 133.41 | |
| Cash And Cash Equivalents | 3.35 | 1.80 | 0.71 | 2.56 | 3.13 | |
| Short Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 23.76 | |
| OtherCurrentAssets | 4.23 | 22.01 | 20.63 | 30.01 | 0.00 | |
| Total Current Assets | 244.05 | 272.01 | 232.51 | 216.61 | 204.04 | |
| Total Assets | 599.78 | 611.99 | 557.29 | 545.77 | 534.20 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 140.38 | 30.40 | 11.05 | 9.20 | 9.71 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 58.56 | 33.09 | 43.12 | 14.18 | 57.55 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 3.83 | 3.19 | 1.33 | 6.95 | 22.06 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 11.28 | 10.84 | 6.97 | 21.12 | 0.00 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | -- | -- | -- | -- | 341.80 | |
| Other Earnings | 426.57 | 408.70 | 281.38 | 206.07 | -- | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | -- | -- | -- | -- | -- | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 236.07 | 236.07 | 236.07 | 234.29 | 231.44 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Buy Marksans Pharma; target of Rs 225: Choice Institutional Equities
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
24.11.2025
Marksans Pharma Standalone September 2025 Net Sales at Rs 320.44 crore, up 3.83% Y-o-Y
22.03.2026
Sell-on-rise market? SBI Securities sees Nifty under pressure, picks two stocks for the week ahead
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
20.03.2026
Semaglutide’s patent expires today. What does it mean for patients, pharma players and Novo Nordisk?
20.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth